Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators

This article was originally published here

The collaboration will see the modular biologics and functional immunology expertise of Pandion combined with the advanced therapeutics development and global commercialisation capabilities of Astellas for the treatment

The post Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply